ArticleFrontiers in oncology2025
The nomogram of contrast-enhanced ultrasound-targeted fusion biopsy predicts the pathology upgrade in prostate cancer.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aim: The aim of this study was to analyze the consistency between the pathology of combined systematic and contrast-enhanced ultrasound (CEUS)-targeted prostate biopsy and radical prostatectomy (RP) by building a nomogram to predict the pathology upgrade of Gleason grade group (GGG). Methods: A total of 113 participants with prostate cancer with combined systematic and CEUS-targeted prostate biopsy followed by RP were recruited between January 2021 and November 2024. The Kappa coefficient of pre- and post-RP GGG was calculated. The independent predictors for pathology upgrade were screened using logistic regression and then applied to build a nomogram for pathology upgrade prediction. The performance of the nomogram was assessed by receiver operating characteristic analysis, calibration curve analysis, and decision curve analysis. Result: Among 113 participants, 25 (22.1%) Gleason grade group upgrading (GGGU) and 88 (77.9%) non-GGGU cases were found. Moderate consistency of prostate cancer GGG between combined systematic and CEUS-targeted prostate biopsy and final RP pathology was found (Kappa = 0.46, Conclusion: The nomogram integrating CEUS-targeted fusion biopsy variables effectively predicted the risk of pathology upgrade in prostate cancer, which showed potential to guide clinicians in optimizing surgical management in patients with prostate cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.